Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study

BACKGROUND & AIMS: Upregulation of hepatic delta‐aminolevulinic acid synthase 1 with accumulation of potentially toxic heme precursors delta‐aminolevulinic acid and porphobilinogen is fundamental to the pathogenesis of acute hepatic porphyria. Aims: evaluate long‐term efficacy and safety of givo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ventura, Paolo, Bonkovsky, Herbert L., Gouya, Laurent, Aguilera‐Peiró, Paula, Montgomery Bissell, D., Stein, Penelope E., Balwani, Manisha, Anderson, D. Karl E., Parker, Charles, Kuter, David J., Monroy, Susana, Oh, Jeeyoung, Ritchie, Bruce, Ko, John J., Hua, Zhaowei, Sweetser, Marianne T., Sardh, Eliane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Genetics and Rare Liver Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299194/
https://www.ncbi.nlm.nih.gov/pubmed/34717041
http://dx.doi.org/10.1111/liv.15090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299194/
https://www.ncbi.nlm.nih.gov/pubmed/34717041
http://dx.doi.org/10.1111/liv.15090

Ejemplares similares